Revance Therapeutics reported $5.89M in Cost of Sales for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Abbvie ABBV:US $ 4341M 157M
Adamas Pharmaceuticals ADMS:US 576K 49K
Aerie Pharmaceuticals AERI:US $ 7.9M 1.72M
ALKERMES ALKS:US 49.56M 3.56M
Biodelivery Sciences International BDSI:US $ 6.36M 2.08M
Bristol Myers Squibb BMY:US $ 2291M 160M
Coherus Biosciences CHRS:US $ 21.28M 4.58M
Eli Lilly And LLY:US $ 1430.8M 522.4M
Endo International Ordinary Shares ENDP:US $ 297.12M 16.31M
Flexion Therapeutics FLXN:US $ 3.73M 1.25M
Gw Pharmaceuticals GWPH:US $ 11.81M 1.39M
Horizon Pharma HZNP:US $ 251.64M 50.64M
JAZZ PHA JAZZ:US $ 145.22M 26.03M
Johnson & Johnson JNJ:US $ 7250M 317M
Merk MRK:US $ 3056M 14M
Neurocrine Biosciences NBIX:US $ 4.2M 1.1M
Pacira Pharmaceuticals PCRX:US $ 34.65M 0.6M
Procter & Gamble PG:US $ 10365M 574M
Revance Therapeutics RVNC:US $ 5.89M 460K
Supernus Pharmaceuticals SUPN:US $ 18.08M 6.94M
Teva Pharmaceutical Industries TEVA:US $ 1989M 2M
Zogenix ZGNX:US $ 1.29M 0.07M